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Summary 
Background The HPTN 071 (PopART) trial showed that a combination HIV prevention package including universal 
HIV testing and treatment (UTT) reduced population-level incidence of HIV compared with standard care. However, 
evidence is scarce on the costs and cost-effectiveness of such an intervention.
Methods Using an individual-based model, we simulated the PopART intervention and standard care with 
antiretroviral therapy (ART) provided according to national guidelines for the 21 trial communities in Zambia and 
South Africa (for all individuals aged >14 years), with model parameters and primary cost data collected during the 
PopART trial and from published sources. Two intervention scenarios were modelled: annual rounds of PopART 
from 2014 to 2030 (PopART 2014–30; as the UNAIDS Fast-Track target year) and three rounds of PopART throughout 
the trial intervention period (PopART 2014–17). For each country, we calculated incremental cost-effectiveness ratios 
(ICERs) as the cost per disability-adjusted life-year (DALY) and cost per HIV infection averted. Cost-effectiveness 
acceptability curves were used to indicate the probability of PopART being cost-effective compared with standard care 
at different thresholds of cost per DALY averted. We also assessed budget impact by projecting undiscounted costs of 
the intervention compared with standard care up to 2030.
Findings During 2014–17, the mean cost per person per year of delivering home-based HIV counselling and testing, 
linkage to care, promotion of ART adherence, and voluntary medical male circumcision via community HIV care 
providers for the simulated population was US$6·53 (SD 0·29) in Zambia and US$7·93 (0·16) in South Africa. In 
the PopART 2014–30 scenario, median ICERs for PopART delivered annually until 2030 were $2111 (95% credible 
interval [CrI] 1827–2462) per HIV infection averted in Zambia and $3248 (2472–3963) per HIV infection averted in 
South Africa; and $593 (95% CrI 526–674) per DALY averted in Zambia and $645 (538–757) per DALY averted in 
South Africa. In the PopART 2014–17 scenario, PopART averted one infection at a cost of $1318 (1098–1591) in Zambia 
and $2236 (1601–2916) in South Africa, and averted one DALY at $258 (225–298) in Zambia and $326 (266–391) in 
South Africa, when outcomes were projected until 2030. The intervention had almost 100% probability of being cost-
effective at thresholds greater than $700 per DALY averted in Zambia, and greater than $800 per DALY averted in 
South Africa, in the PopART 2014–30 scenario. Incremental programme costs for annual rounds until 2030 were 
$46·12 million (for a mean of 341 323 people) in Zambia and $30·24 million (for a mean of 165 852 people) in 
South Africa.
Interpretation Combination prevention with universal home-based testing can be delivered at low annual cost per 
person but accumulates to a considerable amount when scaled for a growing population. Combination prevention 
including UTT is cost-effective at thresholds greater than $800 per DALY averted and can be an efficient strategy to 
reduce HIV incidence in high-prevalence settings.
Funding US National Institutes of Health, President’s Emergency Plan for AIDS Relief, International Initiative for 
Impact Evaluation, Bill & Melinda Gates Foundation.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction 
In 2018, approximately 38 million people were living with 
HIV infection worldwide, with 1·7 million new infections 
that year.1 HIV incidence is decreasing worldwide, but is 
unlikely to reach the UNAIDS Fast-Track target of less 
than 200 000 new infections in 2030.2 Steep reductions in 
incidence are needed to curb the HIV epidemic and its 
associated financial, societal, and health costs. A universal 
HIV testing and treatment (UTT) strategy that includes 
home-based counselling and testing (HBCT) and linkage 
to care in high-prevalence communities has been 
proposed as an important component of HIV prevention 
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programmes.3,4 Four randomised population-based trials 
in sub-Saharan Africa analysed the effectiveness of UTT. 
Two of these trials (Treatment as Prevention5 and 
Sustainable East Africa Research in Community Health6) 
showed no effect on HIV incidence; whereas another of 
the trials (Botswana Combination Prevention Project)7 
showed a 31% decrease in HIV incidence after 3 years 
in intervention communities compared with control 
communities (n=15 per group). The fourth trial, the HIV 
Prevention Trials Network (HPTN) 071 (PopART) study, 
evaluated whether a combination prevention strategy 
including universal testing via HBCT and antiretroviral 
therapy (ART) could be effectively implemented at a 
population level in Zambia and South Africa.8 Within 
2 years, in adults aged 18–44 years, HIV incidence 
was reduced by around 20% in communities receiving 
Research in context
Evidence before this study
We searched PubMed and Embase on Nov 20, 2019, for health 
economic analyses of home-based HIV counselling and testing 
(HBCT) and linkage to care published between Jan 1, 2000, and 
Sept 13, 2019, with the terms “HIV” AND “Africa South of the 
Sahara” AND (“home” OR “community” OR “mass screening” 
OR “testing” OR “screen” OR “diagnosis” OR “counselling”) AND 
(“cost” OR “cost-effectiveness” OR “cost-utility” OR 
“cost-benefit”). We included studies that assessed HBCT against 
facility-based HIV prevention and care, and excluded studies on 
mobile testing, partner notification, and index-linked testing of 
partners or children of HIV-infected individuals. We excluded 
studies that compared universal HIV testing and treatment 
(UTT) against standard care with antiretroviral therapy (ART) 
conditional on CD4 eligibility criteria. These studies would not 
be comparable with our study incorporating universal provision 
of ART as standard care for most years of the projection 
horizon. We included studies that assessed HBCT on its own or 
in combination with screening for an HIV co-infection including 
tuberculosis, but not those that combined it with other 
interventions such as HIV self-testing or diagnosis for other 
conditions. We included modelling and simulation studies that 
were targeted at the general population, that considered effect 
on treatment outcomes of HIV-infected individuals and on the 
incidence of new HIV infections, and that had documented the 
methodology, cost estimates, frequency of testing rounds, and 
projection horizon. We included studies that measured 
effectiveness in terms of disability-adjusted life-years (DALYs) 
averted or quality-adjusted life-years (QALYs) gained, life-years 
gained, or infections averted, but excluded studies that 
measured effectiveness in terms of intervention uptake or 
HIV-positive cases identified. Five studies in Uganda and South 
Africa fulfilled our inclusion criteria. In modelling projections of 
various combination interventions, estimates of cost-
effectiveness varied widely, at US$860–1710 per QALY gained 
or DALY averted, $8639–22 000 per infection averted, 
$474–3400 per life-year saved, and cost-effectiveness 
thresholds greater than $1690 per DALY averted.
Added value of this study
Limited and conflicting evidence is available on the cost-
effectiveness of combination prevention interventions 
including UTT. The findings of this study provide important 
evidence on the benefits and costs of UTT in high-prevalence 
communities. Existing modelling studies are problematic to 
compare because of differences across studies, most notably 
the country settings, features of the intervention that were 
modelled, target population, baseline prevalence, frequency of 
HBCT, and model projection horizon. Previous studies also had 
to rely heavily on simulations and secondary data sources. Until 
now, to the best of our knowledge, there has been no evidence 
from large-scale population randomised studies, and no large-
scale evidence on the effectiveness of a combination prevention 
intervention in reducing HIV incidence. This study used primary 
data collected as part of the HPTN 071 (PopART) trial of a 
combination prevention intervention including UTT, delivered 
via a home-based HIV testing approach in Zambia and 
South Africa. We have evaluated the cost-effectiveness of the 
actual trial intervention implemented between 2014 and 2017, 
projecting outcomes until 2030. In addition, we modelled the 
cost-effectiveness of an annual campaign that is sustained for 
17 years between 2014 and 2030. We projected that the 
PopART intervention implemented annually up to 2030 has 
almost 100% probability of being cost-effective at 
cost-effectiveness thresholds greater than $800 per DALY 
averted in Zambia and South Africa.
Implications of all the available evidence
The estimates of cost-effectiveness from this study are more 
economically favourable than those of previous studies, 
probably due to the projected reductions in HIV incidence 
caused by the intervention, reduction in costs of ART in the past 
years, and the scale at which PopART was implemented. The 
intervention was not cost-saving in either scenario, explained by 
repeated rounds of HBCT, sustained high expenditures on 
treatment from improved linkage to care, and the near normal 
life expectancy of HIV-infected individuals receiving ART. The 
affordability of PopART is an important consideration. Although 
the estimated unit costs of the intervention per person covered 
are low, they accumulate to a considerable amount when 
projected for the total population (age >14 years) to be covered. 
The optimal frequency of intervention rounds is an important 
consideration. Our findings show that three annual rounds 
cannot sustain the initial reduction in incidence, and numbers of 
new infections approach those under standard care after 
13 years. Previous evidence has shown that prevention 
interventions that prioritise specific subpopulations are often 
more cost-effective than interventions that target the general 
population. Our results show that a population-level 
combination prevention strategy can be economically efficient.
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the combination prevention package (n=14), compared 
with communities receiving standard care (n=7).8
To date, PopART is the largest population-level 
randomised controlled trial of a combination prevention 
intervention against HIV that resulted in reduced 
incidence. However, little evidence is available on the 
costs, cost-effectiveness, and budgetary implications of 
such an intervention. An estimate for the cost per person 
tested via HBCT is US$22·8 (SD $14·5), averaged across 
14 studies, with an estimated minimum cost of $6 and 
maximum cost of $55.9 Evidence on cost-effectiveness of 
HBCT is also limited and comes from small studies 
with varying estimates.10–14 Estimates of incremental cost-
effectiveness ratios (ICERs) from three modelling studies 
were $860–1710 per disability-adjusted life-year (DALY) 
averted (or quality-adjusted life-year gained [QALY]),11,13 
and $8639–22 000 per infection averted.11,14 In this 
Article, our aim was to provide evidence from the 
PopART intervention on the costs, cost-effectiveness, 




The HPTN 071 (PopART) trial took place between 
2013 and 2018 (intevention period from November, 2013, 
to December, 2017), in 21 large urban communities in 
Zambia (n=12) and South Africa (n=9) (total population 
approximately 1 million). The 21 trial communities were 
grouped in seven matched triplets based on location and 
HIV prevalence. Within each triplet communities were 
randomly allocated to one of three trial arms: two 
intervention arms (A and B) and a control arm (C). The 
combination prevention inter vention included, amongst 
other components, HBCT delivered by community HIV 
care provider (CHiP) teams, who also supported linkage 
to HIV care, promoted ART adherence, provided 
condoms, and promoted a package of prevention strategies 
among HIV-negative individuals, including voluntary 
medical male circum cision (VMMC). In addition, one 
intervention arm of the trial (seven communities in arm 
A) provided ART irrespective of CD4 count threshold, 
while the other intervention arm (seven communities in 
arm B) provided ART according to national guidelines 
(CD4 threshold of 350 cells per µL in 2013, which increased 
to 500 cells per µL in 2014). Due to the change in national 
guidelines to universal ART, the two intervention arms 
were equivalent from April, 2016 onward in Zambia and 
October, 2016 onward in South Africa. The trial has been 
described in detail previously.8,15 Ethical approval for 
the trial was granted by ethics committees at the 
London School of Hygiene & Tropical Medicine (London, 
UK), the University of Zambia (Lusaka, Zambia), and 
Stellenbosch University (Stellenbosch, South Africa).
For our cost-effectiveness analysis of PopART, we used 
an individual-based simulation model (PopART-IBM),16 
specifically developed to model the trial and informed 
extensively by data collected during the trial. In each 
intervention community (arms A and B), the model 
simulates the HIV epidemic, standard care (for HIV 
counselling and testing and VMMC) and the following 
components of the PopART intervention: universal 
HBCT, linkage to care, promotion of ART adherence, 
and VMMC delivered by CHiPs along with universal 
ART in arm A and ART according to national guidelines 
in arm B. Thus, the two modelled intervention arms 
differ in ART provision for the first 2 years (2014–15) and 
are equivalent for the remainder of the projection period. 
We used the model to estimate the combined cost and 
cost-effectiveness of both intervention arms in PopART 
compared with a counterfactual of standard care provided 
at government clinics, with ART offered according to 
national guidelines.
We modelled two scenarios in men and women 
(appendix 1 p 10) over a time horizon up to 2030 (as the 
UNAIDS Fast-Track target year). The first scenario, 
PopART 2014–30, modelled the PopART intervention 
implemented in annual rounds from 2014 to 2030, 
with the counterfactual simulating standard care. 
The second scenario, PopART 2014–17, modelled the 
PopART inter vention implemented in three annual 
rounds from 2014 to 2017, over the actual trial period and 
then discontinued up to 2030, with the counterfactual 
simulating standard care.
PopART-IBM 
The PopART-IBM (described in appendix 1 [pp 1–5] and 
a preprint paper16) simulates every individual aged older 
than 14 years in a growing heterosexual population of 
approximately the same size as each modelled trial 
community. Demography is modelled from country-
specific, age-specific, and sex-specific mortality and 
fertility rates from the UN Population Division.17 Partner-
ship formation and dissolution are parameterised with 
data from extended questionnaires on sexual behaviour 
collected during the trial.8 Key model and calibration 
parameters are listed in table 1.
HIV is introduced into the simulated population 
between 1975 and 1980 and HIV transmission is 
assumed to only occur in serodiscordant couples. HIV 
disease progression without ART is assumed to occur 
at rates estimated from the AIDS therapy evaluation 
in the Netherlands study (appendix 1 pp 3–4).24 In 
intervention communities, CHiP teams are assumed to 
visit individuals and offer the PopART intervention 
package with a coverage that matches trial data, 
stratified by age and sex. HIV testing, with assumed 
100% sensitivity and specificity, is done at each CHiP 
visit, and individuals with an HIV-positive test result are 
offered ART irrespective of CD4 cell count threshold in 
arm A communities, while in arm B communities 
individuals are offered ART according to national 
guidelines. Time until ART initiation, after an HIV-
positive test result as part of a visit from a CHiP, is 
See Online for appendix 1
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modelled from trial data. In the counterfactual scenario 
of standard care, the epidemic without the PopART 
intervention is simulated with the same parameters 
(table 1) apart from those affected by PopART (testing 
coverage, ART eligibility, and dropout rates). Repeat 
CD4 testing is simulated for those not immediately 
eligible for ART in both the intervention and standard 
care communities (before the introduction of universal 
ART either as part of the PopART intervention from the 
start of the trial in arm A, or from 2016 in arm B and 
the counterfactual).
Individuals starting ART can either become virally 
suppressed, virally unsuppressed, or dropout of care, 
and the risk of HIV transmission to partners is 
dependent on an individual’s position within the care 
cascade. VMMC is offered by CHiPs to any HIV-negative 
male after a negative HIV test (table 1). Thus VMMC 
uptake in the PopART intervention scenarios can occur 
after a negative test by CHiPs or at a health facility, 
making it different from uptake under standard care. 
VMMC is assumed to offer a 60% reduction in 
susceptibility,25,26 while traditional male circumcision is 
assumed to offer no protection according to PopART 
data (appendix 1 p 3). Prevalence of traditional male 
circumcision differs by community according to trial 
data.
The PopART-IBM is calibrated separately to each 
of the 14 trial intervention communities via approxi-
mate Bayesian computation.27 The calibration approach 
(appendix 1 pp 4–5) provides 1000 simulations for the 
intervention and counterfactual standard care in each 
community. For calibration, the PopART-IBM uses trial 
Value or range explored Notes
HIV-related parameters
Start of HIV epidemic, year 1975 (Zambia), 1980 (South Africa) ··
Average annual hazard of an (uncircumcised) man becoming HIV-positive from 
an HIV-positive partner who has maximal set-point viral load
0·05–0·30 Hollingsworth et al (2008);18 Fraser at al (2007)19
Relative infectivity by HIV stage (relative to CD4 count of ≥500 cells per µL) 1·00 (CD4 350–500), 1·00 (CD4 200–350), 
2·34 (CD4 <200), 5·30 (AEHI)
Bellan et al (2015)20
Duration of AEHI, years 0·08–0·25 Bellan et al (2015)20
Relative infectivity of male-to-female transmission (compared with 
female-to-male)
1·0–3·0 Boily et al (2009)21
HIV care-related parameters
Probability of a women having an HIV test under standard care in 2000–06 0·1–0·2 Estimated in the calibration; probability is for a period of 6 years
Annual probability of a women having an HIV test from 2006 onwards under 
standard care
0·05–0·40 Estimated in the calibration
Relative probability of a man having an HIV test under standard care (at any 
time; compared with women)
0·4–1·1 Estimated in the calibration
Probability of collecting HIV test results from an HIV test under standard care 0·97–1·00 Demographic and Health Survey 2013 (Zambia)
Probability of collecting a CD4 test result under standard care 0·75–0·95 Lower limit is from Mugglin et al (2012);22 higher limit assumed
Mean time to starting ART after an HIV-positive test delivered under standard 
care (conditional on starting ART), years
0·4–0·7 Estimated in the calibration
Probability of a women staying virally suppressed for life after ART initiation 0·65–0·90 Estimated in the calibration
Relative probability of a man staying virally suppressed for life (compared with a 
woman)
0·6–1·0 Estimated in the calibration
After ART initiation, probability of an individual becoming virally unsuppressed 
due to suboptimal ART adherence
0·1 Vinikoor et al (2014)23
Relative infectivity of an individual on ART (compared with not being on ART) 0·5 (early ART),* 0·7 (virally 
unsuppressed), 0·0 (virally suppressed)
Values assumed; no transmission from individuals who are virally 
suppressed
Probability of a man accepting VMMC after an HIV-negative test result† 0·4 Assumption cross-checked against population cohort† data




Risk assortativity 0·05–0·95 The propensity for individuals within the same risk group§ to 
form partnerships with those in the same risk group; estimated in 
the calibration
Relative number of sexual partners (compared with self-report) 0·625–5·000 Estimated in the calibration; used to account for misreporting of 
sexual partners
AEHI=acute and early HIV infection. ART=antiretroviral therapy. VMMC=voluntary medical male circumcision. *The 2-month period after initiating ART when an individual is not fully virally suppressed. †Assumed 
to be a fixed probability of VMMC acceptance across the intervention and counterfactual simulations. ‡A random sample of ~2500 individuals aged 18–44 years per trial community (n=21), within which the 
primary endpoint of the trial was measured. §Representing level of sexual activity.
Table 1: Key model and calibration parameters in the PopART individual-based simulation model
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data and national historical surveys (table 1 and appendix 1 
p 5), all stratified by age and sex.
The predictive ability of the model has previously 
been compared against primary and selected secondary 
endpoints of the trial. Projections from PopART-IBM 
included the estimated primary endpoint of the trial 
(relative reduction in cumulative incidence between 
12 and 36 months of the trial) in arm B communities, 
both before and after trial unblinding, and the estimated 
primary endpoint in arm A communities after trial 
unblinding.28 The model calibrated well to the majority 
of the data over time including age-stratified and sex-
stratified HIV prevalence, proportion of people living 
with HIV aware of their status, proportion of people on 
ART among those aware of their HIV status, and 
proportion of people virally suppressed among those 
living with HIV. Detailed results for an intervention 
community in Zambia are available in the preprint 
paper by Pickles and colleagues.16
Projected HIV incidence under PopART 2014–30 and 
PopART 2014–17 is presented by country and sex along 
with 2·5% and 97·5% quantiles of mean incidence from 
the PopART-IBM calibration.
Costs 
We did microcosting studies for both countries to 
derive the costs of the PopART intervention during 
the trial. We collected costs from a health-care provider 
perspective using data from study records, expense 
reports, and consultations with staff at all trial HIV 
care facilities. A combination of ingredients-based and 
activity-based costing was used to estimate the cost 
per person per year covered by CHiPs in the community, 
the additional costs of individuals accepting the CHiP 
intervention, and the costs for persons testing 
HIV-positive or HIV-negative. To isolate the costs of 
HBCT from other com ponents of the combination 
prevention package and research activities, a detailed 
time-and-motion study of CHiP activities was done 
(appendix 1 pp 5–7).
To estimate the cost of ART per person per year, 
detailed costing surveys of all HIV clinics (appendix 1 
pp 7–8) participating in the trial were implemented in 
2015–17. A facility costing tool was developed specifically 
for this study, and collected data on staff numbers, salary 
scales, age and size of buildings, laboratory tests done, 











Basic cost per person covered by CHiPs $5·08 Uniform 
distribution
–20% to 20%‡ PopART study data $6·36 Uniform 
distribution
+ or –20%‡ PopART study data




–20% to 20%‡ PopART study data $16·91 Uniform 
distribution
+ or –20%‡ PopART study data




–20% to 20%‡ PopART study data $10·76 Uniform 
distribution
+ or –20%‡ PopART study data
Cost per person for HIV counselling 
and testing at health-care facility
$4·32 Gamma α=5·50, 
β=0·80
Mwenge et al (2017)29 $4·88 Gamma α=14·75, 
β=0·38
Point estimate from PopART 
study data; range based on 
Meyer-Rath et al (2019)30
Cost per CD4 cell count test $6·48 Gamma α=38·07, 
β=0·16
Cassim et al (2014)31 $6·18 Gamma α=38·07, 
β=0·16
Point estimate from PopART 
study data; range based on 
Cassim et al (2014)31
Cost of ART per person per year $212·50 Gamma α=4·80, 
β=44·38
PopART study data $315·39 Gamma α=9·01, 
β=35·02
PopART study data
Cost per voluntary medical male 
circumcision
$56·16 Gamma α=25·00, 
β=2·25
Vandament et al (2016)32 $129·07 Gamma α=179·64, 
β=0·72
Tchuenche et al (2016)33
Cost of health care for HIV-positive 
person not on ART (CD4 count 
>350 cells per µL)
$5·40 Point estimate ·· Eaton et al (2014)34 $14·04 Point estimate ·· Eaton et al (2014)34
Cost of health care for HIV-positive 
person not on ART (CD4 count 
200–350 cells per µL)
$18·36 Point estimate ·· Eaton et al (2014)34 $49·68 Point estimate ·· Eaton et al (2014)34
Cost of health care for HIV-positive 
person not on ART (CD4 count 
<200 cells per µL)
$68·04 Point estimate ·· Eaton et al (2014)34 $180·36 Point estimate ·· Eaton et al (2014)34
Cost of end-of-life care $54·00 Point estimate ·· Eaton et al (2014)34 $172·80 Point estimate ·· Eaton et al (2014)34
Cost of ART initiation $52·92 Point estimate ·· Eaton et al (2014)34 $102·60 Point estimate ·· Eaton et al (2014)34
Costs are expressed in 2017 US$. PSA=probabilistic sensitivity analysis. CHiP=community HIV care provider. ART=antiretroviral therapy. *Cost parameters with PSA distributions were varied in probabilistic 
sensitivity analysis, whereas cost parameters that constitute point estimates were not. †Range specifies the parameters of the distribution used in the PSA. ‡Since these unit costs were calculated by multiplying 
the per minute cost of a CHiP by the time spent per person covered (appendix 1 pp 6–7), the range varies the time component by + or –20%.
Table 2: Cost parameters
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dispensing and stock levels, drugs dispensed for the 
prevention and treatments of opportunistic infections, 
and general costs for buildings, maintenance, vehicles, 
and utilities. Data were collected from clinic records, 
interviews with key personnel at the facility, local and 
national government offices, non-governmental insti-
tutions, and providers of supply chains. Data on patient 
numbers, drug dispensing, and laboratory tests were 
collated via review of administrative paper records and 
electronic monitoring records. Costs of HIV testing, CD4 
cell count testing, health-care use (for those initiating 
ART, those not on ART, and end-of-life care), and 
VMMC were based on published estimates for Zambia 
and South Africa (table 2). All costs are expressed in 
2017 US$.
Cost-effectiveness and budget impact 
A probabilistic approach to cost-effectiveness analysis was 
applied by attaching costs and disability weights to each 
retained simulation either as point estimates or by varying 
key cost parameters (table 2, appendix 1 pp 8–9, 26), 
generating 1000 estimates of the intervention and 
counterfactual standard care costs and health outcomes 
(DALYs and new infections), in each of the 14 com -
munities. All cost components listed in table 2 were 
included in the cost-effectiveness analysis. Disability 
weights were drawn from the Global Burden of Disease 
Study 2010 (appendix 1 p 26).35 Using a random ordering 
of the 1000 estimates in each community, we totalled 
costs and health outcomes across the 14 intervention 
communities, generating estimates of total cost, total 
DALYs, and total infections under the intervention and 
counterfactual approaches. DALYs and infections averted 
are presented in box plots with median and IQR values, 
and as percentage of infections and DALYs averted with 
the intervention compared with the counterfactual 
standard care. For each estimate of total cost and health 
outcomes (DALYs or infections), ICERs of the intervention 
compared with standard care were calculated as the 
difference in total cost between the intervention and 
counterfactual, divided by the difference in total health 
outcomes. Results are summarised as median ICERs 
and 95% credible intervals (CrIs). In calculating ICERs, 
PopART 2014–30 and PopART 2014–17 were indepen-
dently compared with standard care. The three strategies 
were not incrementally compared with each other as 
PopART 2014–30 is our primary intervention scenario 
from a policy perspective to reach the UNAIDS 2030 
Fast-Track target. Uncertainty in ICERs across parameter 
draws was summarised via a cost-effectiveness plane with 
a corresponding 95% credible ellipse.
We present two outcome measures from a health-care 
system perspective: cost per infection averted and cost 
per DALY averted. Future total costs and total health 
outcomes were discounted at an annual rate of 3%.36,37
Cost-effectiveness acceptability curves are presented to 
summarise the probability of the intervention being cost-
effective at different thresholds of cost per DALY averted. 
Model projections were used in a budget impact analysis, 
projecting the undiscounted costs of the intervention 
compared with counterfactual standard care up to 2030 in 
the PopART 2014–30 scenario. Average cost per person 
per year of delivering universal HBCT, linkage to care, 
promotion of ART adherence, and VMMC via CHiPs over 
the trial period was estimated by dividing the total 
projected CHiP costs for these components by the 
simulated population older than 14 years.
As a sensitivity analysis, we evaluated the effect of 
discount rate and time horizon on ICERs by varying the 
discount rate at 1% and 8%, and the time horizon in 
increments of 5 years (2035 and 2040). We also present 
ICERs by trial arm as a further sensitivity analysis to 
identify potential differences due to ART eligibility 
for 2014–15. Additionally, we did a one-way parameter 
sensitivity analysis, in which we individually varied four 
epidemiological parameters not varied in the PopART-
IBM calibration (misreporting of partnership formation 
rates, relative infectivity of acute and early HIV infection 
compared with CD4 ≥500 cells per µL, CD4 progression 
when on ART but virally unsuppressed, and partnership 
Figure 1: Health effects of the PopART intervention under different scenarios
Box plots show the median (IQR) for 1000 retained simulations of new HIV infections and DALYs averted in Zambia 
and South Africa in 2014–30. Outliers were calculated as datapoints greater or less than 1·5× the IQR from upper 
and lower IQR values. (A and C) PopART 2014–30 scenario: PopART intervention implemented in annual rounds 
between 2014 and 2030. (B and D) PopART 2014–17 scenario: PopART intervention implemented in three annual 
rounds between 2014 and 2017 and then discontinued up to 2030. DALY=disability-adjusted life-year. 
The simulated mean annual population covered in 2014–30 (accounting for population growth) was 341 323 in 
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formation between trial communities and immediate 
neighbourhoods) and three cost parameters relating to 
the PopART intervention (cost per person per year on 
ART, cost per VMMC, and per-min cost of CHiPs; 
appendix 1 pp 28–29) while holding others at their central 
estimate in the PopART-IBM or point estimates of costs 
(appendix 1 p 9). Resulting effect on ICERs is summarised 
in tornado plots.
Role of the funding source 
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report.
Results 
The greatest HIV incidence reductions were projected 
(appendix 1 p 10) in the PopART 2014–30 scenario, in 
which the intervention is implemented annually for 
17 years. By contrast, in the PopART 2014–17 scenario, an 
initial decrease in incidence during three annual rounds 
of PopART between 2014 and 2017 is followed by an 
increase in incidence from 2019, almost approaching 
incidence in the counterfactual standard care scenario by 
2030. In the PopART 2014–30 scenario, a median of 
22 769 (IQR 21 599–23 975; 48·7%) new HIV infections in 
Zambia and 9805 (9069–10 729; 38·6%) new HIV 
infections in South Africa could be averted when 
compared with standard care. Additionally, a median of 
86 413 (82 547–90 452; 39·8%) DALYs in Zambia and 
52 961 (39·5%) DALYs in South Africa could be averted 
(figure 1, table 3). In the PopART 2014–17 scenario, 
11 110 (10 349–11 832; 23·7%) new HIV infections in 
Zambia and 5026 (19·8%) new infec tions in South Africa 
could be averted; and 64 305 (61 155–67 601; 29·6%) 
DALYs in Zambia and 39 239 (36 773–41 744; 29·2%) 
DALYs in South Africa could be averted, compared with 
standard care. Projected population sizes were notably 
different between the countries, with a mean annual 
population simulated in 2014–30 of 341 323 in Zambia 
and 165 852 in South Africa.
During 2014–17, the mean cost per person per year of 
delivering universal HBCT, linkage to care, promotion of 
ART adherence, and VMMC via CHiPs in the simulated 
population older than 14 years was $6·53 (SD 0·29) 
in Zambia and $7·93 (SD 0·16) in South Africa. The 
PopART 2014–30 scenario produced median ICER values 
of $2111 (95% CrI 1827–2462) per HIV infection averted in 
Zambia and $3248 (2472–3963) per HIV infection averted 
in South Africa; and $593 (526–674) per DALY averted 
in Zambia and $645 (538–757) per DALY averted in 
South Africa, compared with standard care (table 3). The 
entire ICER distribution for both HIV infections and 
DALYs averted implied PopART could avert more 
infections and DALYs than standard care, but at higher 
costs (figure 2). The ICER per HIV infection or DALY 
averted was lower in the PopART 2014–17 scenario with 
discontinuation of the intervention. In this scenario, 
PopART averted one infection at a cost of $1318 
(1098–1591) in Zambia and $2236 (1601–2916) in South 
Africa, and one DALY at a cost of $258 (225–298) in 
Zambia and $326 (266–391) in South Africa, when 
outcomes were projected until 2030 (figure 2 and table 3). 
However, as shown by our projections (appendix 1 p 10), 
discontinuation of the intervention would result in 
increased HIV incidence after an initial decrease.
Cost-effectiveness acceptability curves (figure 3) 
showed almost 100% probability of the intervention 
being cost-effective at thresholds greater than $700 
Zambia South Africa
PopART 2014–30 PopART 2014–17 PopART 2014–30 PopART 2014–17
Cost
Mean cost per person per year during the 
trial period* 
$6·53 (0·29) $6·53 (0·29) $7·93 (0·16) $7·93 (0·16)
Cost-effectiveness
ICER: cost per HIV infection averted $2111 (1827–2462) $1318 (1098–1591) $3248 (2472–3963) $2236 (1601–2916)
ICER: cost per DALY averted $593 (526–674) $258 (225–298) $645 (538–757) $326 (266–391)
Health gains and budget impact
Annual cost of PopART during the trial 
period (undiscounted)
$3·98 million (2014),  
$4·44 million (2015), $4·58 million 
(2016), $4·88 million (2017)
$3·98 million (2014),  
$4·44 million (2015), $4·58 million 
(2016), $4·88 million (2017)
$2·61 million (2014),  
$3·10 million (2015), $3·17 million 
(2016), $3·25 million (2017)
$2·61 million (2014),  
$3·10 million (2015), $3·17 million 
(2016), $3·25 million (2017)
Incremental cost (undiscounted) $46·12 million (115·0%) $12·67 million (31·8%) $30·24 million (118·2%) $9·89 million (38·7%)
Incremental HIV infections averted 
(undiscounted)
22 769 (48·7%) 11 110 (23·7%) 9805 (38·6%) 5026 (19·8%)
Incremental DALYs averted (undiscounted) 86 413 (39·8%) 64 305 (29·6%) 52 961 (39·5%) 39 239 (29·2%)
Costs are expressed in 2017 US$. ICERs are the median and 95% credible intervals for 1000 simulations. Other data are presented as the mean (SD) or absolute value (percentage of counterfactual standard care). 
Incremental values represent the difference between the intervention compared with counterfactual simulations. ICER=incremental cost-effectiveness ratio. DALY=disability-adjusted life-year. *Includes home-
based HIV counselling and testing, linkage to care, promotion of antiretroviral therapy adherence, and voluntary medical male circumcision, delivered by community HIV care providers to the population older 
than 14 years.
Table 3: Key cost, cost-effectiveness, health gain, and budget impact results by scenario
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per DALY averted in Zambia, and greater than 
$800 per DALY averted in South Africa, in the PopART 
2014–30 scenario. In the PopART 2014–17 scenario, these 
thresholds were $350 per DALY averted in Zambia 
and $450 per DALY averted in South Africa.
During the trial period (2014–17), the annual costs of 
delivering HIV care, including the PopART intervention, 
for the simulated population older than 14 years ranged 
from $3·98 million to $4·88 million in Zambia and from 
$2·61 million to $3·25 million in South Africa (table 3). 
We projected these costs to increase over the simulation 
period in the PopART 2014–30 scenario (figure 4A, 4B). A 
similar trend was evident in the counterfactual simulating 
standard care. The larger cost increase in Zambia is most 
likely explained by population growth and an increasing 
number of people living with HIV on ART. The magnitude 
of differences in annual costs between countries can be 
attributed to different population sizes. The estimated 
undiscounted incre mental cost of implementing the 
PopART intervention for the entirety of 2014–30 over 
standard care was $46·12 million (115·0%) in Zambia 
and $30·24 million (118·2%) in South Africa (table 3). 
We identified CHiPs and ART to be the two most 
costly components. These components would incur 
similar costs in Zambia, whereas the cost of ART would 
exceed that of CHiPs in South Africa during 2014–30 
(figure 4C, 4D).
Varying the discount rate in our sensitivity analysis 
resulted in small changes in the estimated ICERs 
(appendix 1 p 27). Increasing the model time horizon to 
2035 and 2040 resulted in successively lower ICERs 
compared with the 2030 projections, as future health 
benefits and cost savings from reduced incidence have a 
greater effect than the cost outlay (appendix 1 p 28). 
Analysis by trial arm resulted in small changes in the 
estimated ICERs with slightly larger ICERs in arm B, 
which had ART according to CD4 thresholds in the first 
two simulation years (appendix 1 p 28). One-way 
parameter uncertainty analysis showed ART costs and 
the extent of misreporting of partnership formation to 
have the greatest effect on ICERs (appendix 1 p 25).
Discussion 
Universal HBCT, linkage to care, promotion of ART 
adherence, and VMMC can be delivered via CHiPs at scale 
at low cost, at $6·53 per person per year in Zambia and 
$7·93 per person per year in South Africa. PopART 
delivered over three rounds is cost-effective if policy 
Figure 2: Cost-effectiveness planes
Incremental cost-effectiveness ratios for PopART 2014–30 and PopART 2014–17 
scenarios compared with standard care. Graphs show simulations, with median 
cost plotted against median effect. (A and C) Incremental costs and HIV 
infections or DALYs averted in the PopART 2014–30 scenario. (B and D) 
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makers have a cost-effectiveness threshold of at least 
$350 per DALY averted in Zambia and $450 per DALY 
averted in South Africa. Delivered in annual rounds for 
17 years (2014–30), PopART is cost-effective at thresholds 
greater than $800 per DALY averted. Although programme 
costs are high for annual implementation up to 2030, they 
correspond to a maintained effect on HIV incidence, 
whereas lower costs for a 3-year implementation are offset 
by a non-sustained reduction in HIV incidence.
In comparison with other studies,10–14 our ICER estimates 
are lower, suggesting that the cost-effectiveness of 
combination prevention including HBCT and promotion 
of VMMC, in addition to ART, at the population level is 
greater than previously thought. Two studies on HBCT 
estimated ICERs of $860–1710 per QALY13 at increasing 
ART thresholds (up to a CD4 count <500 cells per µL), 
and an ICER of $1360 per DALY averted with universal 
ART.11 A third study concluded that a combination 
prevention intervention is cost-effective at willingness-to-
pay thresholds greater than $1690 per DALY averted.10 
ICER estimates for HBCT in terms of infections averted 
were markedly higher at $11 4809 and $8750–22 000.11 
However, previous studies differ in several key features 
from our study, most notably the frequency of testing 
rounds every 6 months12 or every 2 years,12,14 4 years,11 or 
5 years13 (vs annual rounds in the PopART trial) and 
projection over 10 years,11–13 14 years,10 or 20 years.14 
Generally, cost-effectiveness analyses are sensitive to 
future incidence projections;14 therefore differences in 
the epidemiological models might explain part of the 
variations in estimates. Studies also differed in the 
effectiveness of the intervention, as measured 
by its coverage, linkage to care, coverage of ART, and 
viral suppression. Three studies used data from rural 
communities,11–13 and the low population density and 
small scale of delivery might have resulted in higher 
implementation costs compared with the urban and 
peri-urban communities in PopART. Additionally, the 
reduction in drug costs in the past 10–15 years could be 
important in explaining the lower cost-effectiveness in 
previous studies. ICER estimates have been shown to 
vary with the costs of ART drugs and care, particularly if 
there is no eligibility criteria for ART initiation.11,13 
Previous studies assumed the per person per year costs 
of ART at $68213 and $565,11 which are higher than our 
estimated costs of ART at $212 (Zambia) and $315 (South 
Africa).
Is a combination intervention including UTT worth 
implementing as part of standard of care in high 
prevalence settings? Our findings suggest PopART 
should be con sidered for implementation or integration 
into existing government programmes. Compared with 
facility-based care provision, PopART could generate 
substantial health gains. These health gains would be 
due to reduced incidence, resulting from improved 
linkage to care and retention in care of previously 
undiagnosed and untreated HIV-infected people, and the 
success of ART in extending lifespan nearly up to that of 
uninfected people.38,39 However, the annual cost of 
PopART is not outweighed by the cost savings to the 
health-care system that arise from averting new 
infections. The decision to invest in PopART depends 
ultimately on the cost-effectiveness threshold of policy 
makers and donors supporting HIV programmes, with 
such a threshold being the decision criteria for when 
benefits from a new intervention are considered 
sufficient in comparison with its costs.40 Policy makers 
and donors in high prevalence settings can use our cost-
effectiveness acceptability curves to identify the likelihood 
of PopART being cost-effective for their threshold. 
Estimates published in 2016 of cost-effectiveness 
thresholds had a wide range, reflecting the data 
constraints and methodological difficulties in reliably 
estimating thresholds.40 Donors’ thresholds might also 
differ from those of a country’s policy maker due to 
different budget constraints and valuations of health 
benefits based on funding priorities. In cases in which 
Figure 3: Cost-effectiveness acceptability curves by cost per DALY thresholds
Cost-effectiveness acceptability curves represent the probability that the 
intervention is cost-effective across the simulations at specific thresholds of cost 
per DALY averted. DALY=disability-adjusted life-year.
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PopART might not lie within a country’s threshold, 
donors have a role in subsidising its implementation to 
the point that it does become cost-effective. Such an 
approach does not crowd out domestic financing, while 
ensuring a fair and sustainable allocation of aid with 
time as countries move to lower-middle-income and 
middle-income status and donors become more selective 
in the programmes they finance.41
The affordability of PopART is an important 
consideration. Although the estimated average costs of 
the intervention per person covered are low, they sum up 
to a considerable amount when projected for the total 
population older than 14 years. Population growth needs 
to be factored in, because expenditures on combination 
prevention with UTT will increase simply due to the 
increasing population that needs to be covered by the 
intervention. The optimal frequency of testing rounds 
subject to the available budget might be an important 
consideration. We show that three rounds cannot sustain 
the initial reduction in incidence, and numbers of new 
infections approach those under standard care after 
13 years. A modelling study of an HBCT campaign in 
western Kenya showed that in 20 years, DALYs averted 
could be maximised with a so-called front-loaded 
scenario, whereby four testing rounds are delivered in 
years 1, 2, 4, and 8, compared with a scenario of five equally 
spaced rounds every 4 years.42 More research is needed 
exploring alternative and sustainable approaches to HIV 
test provision, including initial door-to-door testing 
followed by mobile or hub-based testing, self-testing,43,44 
or potentially decreasing the frequency of door-to-door 
testing.
This study has limitations. Technological innovation, 
prices of testing and treatment, guidelines, efficacy of 
standard care, behaviour of individuals, population 
dynamics, valuation of health outcomes, and many 
other factors are likely to change in 17 years and affect 
costs and benefits. Although we used detailed costing 
approaches to precisely allocate shared inputs when 
costing HIV care at health-care facilities and to separate 
the research and implementation costs of PopART, the 
likelihood of inaccuracies remains in some of our costs. 
Costs across communities also vary substantially, and 
the extent to which our results are generalisable to 
Figure 4: Budget impact of the PopART 2014–30 scenario
Projected undiscounted annual cost (all cost components) in intervention communities and standard care (counterfactual) communities in the PopART 2014–30 
scenario in Zambia (A) and South Africa (B). Projected undiscounted costs totalled for the period 2014–30 by cost component in Zambia (C) and South Africa (D). 
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other settings depends on their similarity to PopART 
trial communities, including HIV prevalence, and costs 
of hospitalisation and end-of-life care. The generalisability 
of results also depends on the scale and efficiency of 
implementation by public providers if adopted as part of 
a national programme. To address this limitation, we 
allowed for wide variations in crucial parameters in 
sensitivity analyses. In addition, if policy makers are 
considering scale-up to national levels, our estimates do 
not account for potential diminishing marginal returns 
from provision of HBCT to hard-to-reach populations. 
Migration between communities within and outside of 
the study is also likely to affect both benefits and costs, 
and it is difficult to ascertain whether and in what 
direction this might have biased our results.
Several objections are commonly put forward against 
large-scale, population-level combination prevention 
interventions. The yield or positivity rate of screening 
interventions targeted at the general population is low. 
Our findings on cost-effectiveness show that focusing on 
testing yield as an outcome measure is too simplistic. 
This measure does not recognise that combination 
prevention, as we have modelled, affects population 
health via several pathways, which are all captured in the 
overall DALYs and infections averted as measures of 
the ultimate health gain of the intervention. Another 
objection is that an unknown proportion of individuals 
who have newly tested as HIV-positive are retested. 
However, this is not necessarily a waste of resources 
because studies have shown that linkage to care is 
increased in individuals who had previously dropped out 
of care.14,45 Prevention interventions that prioritise specific 
subpopulations on the basis of risk factors are often 
more cost-effective than interventions that target the 
general population, at least in the short term.46 However, 
targeted interventions often have only modest effect 
on population-level HIV incidence and mortality.14 Our 
results show that population-level strategies can be 
delivered at scale at low per-person cost and generate 
substantial health gains. The cost-effectiveness depends 
on the specific thresholds for health gains of policy 
makers and donors. The findings of our study should 
help to identify worthwhile investments into HIV 
interventions and support epidemic control.
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